Microdosing sema — 0.1-0.2mg/week experiences. Minimal side effects, real benefits?

0.1mg/wk here, 8 months. HbA1c 5.8 -> 5.3, fasting insulin 11 -> 6, HOMA-IR halved. Goal was metabolic not cosmetic. Weight dropped 7lb as a side effect. This is a real use case that the label doesn't acknowledge because the trials were powered on weight endpoints.

Microdosing is underserved by the literature because trials don't run there, so all the evidence is N=1 anecdote. That said, the mechanism plausibility is strong — GLP-1 receptor signaling is dose-responsive, you can get meaningful effect below the weight-loss threshold. Just flag it's extrapolation.

@showmethestudy agreed. I wouldn't tell anyone to replace a prescribed T2D protocol with 0.1mg microdose. But as an adjunct to diet/exercise for a pre-diabetic trajectory, the risk/benefit looks very favorable to me.

0.2mg since February. Biggest unexpected benefit was alcohol — I just... stopped wanting to drink. Two glasses of wine a week at most now, down from a bottle. Nobody told me this would happen.

ApoB dropped 18 points on 0.15mg over 6 months for me. Didn't change diet meaningfully. Would have needed a statin otherwise. I'm keeping this going indefinitely.

Stacking microdose sema with microdose cagrilintide (0.2mg each weekly) has been the cleanest protocol I've run. Amylin analogs synergize with GLP-1 and at low doses the side effect profile stays negligible. Food noise is genuinely silent.

This whole thread is why I read here. Label-centric discourse on GLP-1s misses 70% of the real-world use cases.

@cautious_ox I had mild nausea the first 2 weeks then nothing. Some people don't even get that. At 0.1mg you're so far below the nausea-inducing level that most people feel nothing. That's the point.

Question — at 0.1-0.2mg are you seeing any side effects I should expect if I try this? Or is it genuinely sub-threshold?